| |
| |
| Exchange: |
Nasdaq Small Cap |
| Security
Type: |
Common |
| Shares
Out: |
77,400,000 |
| Market
Cap: |
687.31(M) |
| Last
Volume: |
924,004 |
Avg
Vol: |
1,535,793 |
| 52
Week Range: |
$4.32 - $9.91 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile SIGA Technologies is a commercial-stage pharmaceutical company focused on the health security markets. Co.'s primary product, TPOXX®, is a U.S. Food & Drug Administration-approved oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-04 |
2023-11-03 |
2023-05-05 |
2022-05-05 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Townsend Frances F |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
32,000 |
|
- |
|
| Stern Andrew L |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
32,150 |
|
- |
|
| Savas Paul G |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
91,840 |
|
- |
|
| Marshall Joseph W Iii |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
45,000 |
|
- |
|
| Antal James |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
41,154 |
|
- |
|
| Weiner Michael Md |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Kindler Jeffrey B |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Bevins William C |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
80,000 |
|
- |
|
| Bayer Michael J |
Director |
– • – |
2014-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
15,000 |
30,000 |
|
- |
|
| Weiner Michael Md |
Director |
– • – |
2014-03-13 |
4 |
S |
$3.19 |
$47,850 |
D/D |
(15,000) |
0 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• – – |
2014-02-28 |
4 |
D |
$3.21 |
$13,736 |
D/D |
(4,279) |
33,519 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• – – |
2014-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,666 |
37,798 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• – – |
2014-02-28 |
4 |
D |
$3.21 |
$28,919 |
D/D |
(9,009) |
87,124 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• – – |
2014-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
96,133 |
|
- |
|
| Rose Eric A Md |
Chief Executive Officer |
• • – |
2014-02-28 |
4 |
D |
$3.21 |
$88,240 |
D/D |
(27,489) |
472,897 |
|
- |
|
| Rose Eric A Md |
Chief Executive Officer |
• • – |
2014-02-28 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
500,386 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• – – |
2014-01-03 |
4 |
D |
$3.35 |
$34,880 |
D/D |
(10,412) |
71,133 |
|
- |
|
| Hruby Dennis E |
VP & Chief Scientific Officer |
• – – |
2014-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
81,545 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• – – |
2014-01-03 |
4 |
D |
$3.35 |
$47,024 |
D/D |
(14,037) |
26,132 |
|
- |
|
| Luckshire Daniel J |
Executive VP & CFO |
• – – |
2014-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,333 |
40,169 |
|
- |
|
| Rose Eric A Md |
Chief Executive Officer |
• • – |
2014-01-03 |
4 |
B |
$0.00 |
$0 |
I/I |
0 |
13,300 |
2.58 |
- |
|
| Rose Eric A Md |
Chief Executive Officer |
• • – |
2014-01-03 |
4 |
D |
$3.35 |
$97,261 |
D/D |
(29,033) |
433,720 |
|
- |
|
| Rose Eric A Md |
Chief Executive Officer |
• • – |
2014-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
66,666 |
462,753 |
|
- |
|
| Haynes William J Ii |
Executive VP & General Counsel |
• – – |
2014-01-03 |
4 |
D |
$3.35 |
$37,061 |
D/D |
(11,063) |
13,937 |
|
- |
|
| Haynes William J Ii |
Executive VP & General Counsel |
• – – |
2014-01-03 |
4 |
OE |
$0.00 |
$0 |
D/D |
25,000 |
25,000 |
|
- |
|
355 Records found
|
|
Page 9 of 15 |
|
|
0.07 (0.79%) 
